---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Co-prescribed/Concomitant therapies. Topics: Required background ACE inhibitor or ARB in AMPLITUDE, Permitted concomitant kidney therapies in AMPLITUDE at a stable dose, Excluded concomitant medications in AMPLITUDE: QT-prolonging drugs, Inaxaplin added to standard of care in AMPLITUDE, and 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Required background ACE inhibitor or ARB in AMPLITUDE

> “On a stable, maximum tolerated labeled dose (at least 4 weeks before screening) of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), but not both concomitantly, unless documented to be intolerant to ACE inhibitor/ARB.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.12-2"></a>

### Permitted concomitant kidney therapies in AMPLITUDE at a stable dose

> “Subjects taking sodium glucose co transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonist (GLP 1a), mineralocorticoid receptor antagonists (MRAs), endothelin antagonists, sparsentan, or permitted immunosuppressants (prednisone ≤10 mg or steroid equivalent, mycophenolate, tacrolimus, cyclosporine, or azathioprine) must have been on a stable dose for 4 weeks before screening.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.12-3"></a>

### Excluded concomitant medications in AMPLITUDE: QT-prolonging drugs

> “Risk factors for Torsade de Pointes (e.g., familial long QT syndrome, chronic hypokalemia, heart failure) or concomitant medications that prolong the QT/QTc interval or any history of cardiac disorders”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-2.1.2.12-4"></a>

### Inaxaplin added to standard of care in AMPLITUDE

> “Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.2.12-5"></a>

### Background therapy in AMPLIFIED: optimized standard of care

> “In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care.”
> “These patients were already well treated with foundational chronic kidney disease therapies and treatment with inaxaplin led to additional reductions in proteinuria.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.2.12-6"></a>

### Background therapy in the phase 2a study: stable standard-care medications

> “Participants were required to continue taking stable doses of standard-care medications from at least 28 days before commencing inaxaplin through follow-up. Such medications could include, but were not limited to, systemic glucocorticoids (prednisone at a dose of ≤10 mg per day or equivalent), immunosuppressants (tacrolimus, cyclosporine, or mycophenolate mofetil), and renin–angiotensin–aldosterone inhibitors.”
> “As a condition of participation in the study, we prohibited travel during the study to countries where African sleeping sickness (African trypanosomiasis) is endemic.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

> “Patients were on a stable standard-of-care regimen, which could include an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), immunosuppressants and/or low doses of corticosteroids.”
> “Results were consistent regardless of baseline proteinuria or background therapy.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
